PhaseBio preclinical data

In a mouse model of DMD, thrice-weekly 1.5 mg/kg subcutaneous PB1046 for 32 weeks ameliorated DMD myopathies, slowed cardiac deterioration and protected skeletal muscle by reducing fibrosis vs. saline...